A case that explores the impact of financial incentives from insurance companies on the patient-physician relationship and whether or not they should be disclosed to a patient.
An ethical case describes the use of a pharmacy's database to market directly to their patients without either patient consent or disclosure of the marketing intent of the materials they received.
The authors of a recent journal article believe that most doctors and clinical trial sponsors would not object to changes in regulations requiring doctors to disclose financial incentives to their patients.
Adrienne W. Henize, JD and Andrew F. Beck, MD, MPH
Data on certain chronic conditions’ prevalence, incidence of potentially preventable morbidity, and health-harming legal factors influence approaches to care.
AMA J Ethics. 2024;26(8):E648-654. doi:
10.1001/amajethics.2024.648.
AMA Code opinions about collaborative care, health inequity, financial barriers to health care access, and physician responsibilities for safe patient discharge from health care facilities can apply to MLPs.
AMA J Ethics. 2024;26(8):E622-625. doi:
10.1001/amajethics.2024.622.